Goebeler M, Csörgő Sándorné Bata Zsuzsanna, De Simone C., Didona B, Remenyik Éva, Reznichenko N, . . . Kollaborációs szervezet: ARGX-113-1701 Investigator Study Group. (2022). Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: A phase II multicentre, open-label feasibility trial.
Chicago Style (17th ed.) CitationGoebeler M, et al. Treatment of Pemphigus Vulgaris and Foliaceus with Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open-label Feasibility Trial. 2022.
MLA idézésGoebeler M, et al. Treatment of Pemphigus Vulgaris and Foliaceus with Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open-label Feasibility Trial. 2022.
Figyelem: ezek az hivatkozások nem 100%-ban pontosak..